Fig. 4
Anti-tumor efficacy and safety of neoantigen nanovaccines. a Treatment schema of neoantigen nanocaccines. C57BL/6 mice were implanted with B16F10 melanoma cells (2 × 105) on the left lower skin of abdomen on Day 0. About 3 days later, when the tumor size was almost 50 mm3, the tumor was surgically removed (surgical margin: tumor-cell positive). Mice received treatments on Day 6, 8, 10, 12 and 14. b Growth curves represent the average tumor volumes of each group. (n = 10). c Tumor growth curves of each mouse in different groups. (n = 10). P-values were determined by two-way ANOVA with Tukey’s HSD multiple comparison post hoc test. *P = 0.0115 (NS vs Free vaccine), ***P < 0.001. d MRI images of representative mice were taken on Day 20. The tumor of each mouse was circled. e Survival curves. (n = 10). P-values were determined by Log-rank (Mantel-Cox) test. *P = 0.0135 (NS vs Free vaccine), *P = 0.0254 (NS vs Free vaccine). f Body weights of mice in each group. (n = 10). g Hematoxylin–eosin staining of main organs, including heart, lung, liver and kidney. Scale: 100 μm. P-value: *, P < 0.05; ***, P < 0.001